BioSpace News Archive

IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $4.000 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,750,000 shares of its common stock at a price to the public of $3.999 per pre-funded warrant, in each case less underwriting discounts and commissions.

Health-Minded, Mission-Focused, and Inclusive Environment Among Reasons for Selection

The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS’s unique free service providing clinical trials navigation and support to blood cancer patients and their families

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) announced today the strengthening of its Board of Directors (the “Board”) with the intention to appoint a new independent director, Jackie Poriadjian-Asch, on and effective December 10, 2019.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today issued the following statement on behalf of the Board of Directors and management team

Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals,

Shineco, Inc. (“Shineco” or the “Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp products, and various health and well-being focused plant-based products in China, announced today that it completed its first board meeting (the “Meeting”) for fiscal year 2019 held on November 26, 2019 in Beijing, China

Industry leader Host Defense Mushrooms showcases excellence in research with new publication in high-impact, open access journal

Walgreens Boots Alliance, Inc. will release its fiscal 2020 first quarter earnings results at 7 a.m. Eastern time Wednesday, January 8, 2020 followed by a one-hour conference call with Walgreens Boots Alliance management beginning at 8:30 a.m. Eastern time.

Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, announced that founder Dr. Suzanne Ildstad will present a poster at the American Society of Hematology annual meeting, taking place December 7-10, 2019, in Orlando, Fla.